Sexually transmitted infection rates continue to rise in many parts of the world, driven by persistent social stigma, under-investment, and inequitable access to prevention and care, according to the Journal of the International AIDS Society (JIAS). To address these growing public health challenges, JIAS released a new open-access peer-reviewed supplement titled “Towards Elimination of Sexually Transmitted Infections: Research Developments and Vaccine Uptake.”
Overcoming Stigma and Implementation Barriers in STI Prevention
Stigma remains a barrier to vaccine acceptance, according to the JIAS supplement. Guest editors Jeanne Marrazzo of the Infectious Diseases Society of America, Nelly R. Mugo of the University of Washington and the Kenya Medical Research Institute, and Yves Levy of the Vaccine Research Institute and Inserm Université Paris Est Créteil highlight that achieving progress will require more sustained investment and global commitment.
Despite remarkable advances in vaccine science, sexually transmitted infections (STIs) remain a persistent and growing global health challenge. The collection examines how social factors intersect with implementation science to shape the global prevention landscape, including strategies to improve access to and uptake of both existing STIs vaccines and those currently in development.
Leveraging Modern Biomedical Technologies for STI Vaccines
Recent breakthroughs in mRNA technology, artificial intelligence, structural biology, novel adjuvants, and vaccine delivery systems are transforming the biomedical field. The JIAS supplement explores how researchers can harness this scientific momentum to accelerate the development of new sexually transmitted infection vaccines.
Translating those same successes to sexually transmitted infections requires dedicated funding and targeted global commitments. Guest editors Marrazzo, Mugo, and Levy note that sustained investment is vital to bridge the gap between laboratory discovery and population-level impact.
Did You Know? The Journal of the International AIDS Society specifically encourages submissions in implementation sciences to help translate laboratory research into real-world clinical practices.
Frequently Asked Questions
What is the focus of the new JIAS supplement?
The JIAS supplement focuses on research developments and vaccine uptake regarding sexually transmitted infections, addressing scientific, social, and implementation challenges.
Who served as guest editors for the collection?
The collection was guest edited by Jeanne Marrazzo (Infectious Diseases Society of America, USA), Nelly R. Mugo (University of Washington, USA, and Kenya Medical Research Institute, Kenya), and Yves Levy (Vaccine Research Institute/Inserm Université Paris Est Créteil, France).
What biomedical advancements are discussed in the research?
The articles examine how modern innovations like mRNA technology, artificial intelligence, structural biology, novel adjuvants, and advanced vaccine delivery systems can be applied to STI prevention.
Where can researchers access the published collection?
The supplement is openly available through the Journal of the International AIDS Society website.
Join the Conversation
What strategies do you think are most effective for overcoming stigma in public health campaigns? Share your thoughts in the comments below or explore our related research coverage for more insights.
Worth a look